


9-10 October 2009 | Brussels, Belgium

# EXPERT PRACTICE<sup>SM</sup> in Genitourinary Malignancy



## FACULTY

Lee Lokey, MD, USA (Moderator)  
Peter Mulders, MD, PhD, The Netherlands (Chair)  
Kurt Miller, MD, Germany  
Camillo Porta, MD, Italy  
Thomas Powles, MD, United Kingdom  
Alastair W. S. Ritchie, MD, United Kingdom

We are pleased to invite you to the Expert Practice<sup>SM</sup> in Genitourinary Malignancies meeting in Brussels, Belgium, on 10 October 2009.

During this case-based meeting, leaders in the field will discuss, in an interactive format, clinical issues encountered daily with practicing oncologists.

Register online at [www.primeoncology.org](http://www.primeoncology.org)  
For more information please contact:  
[info@primeoncology.org](mailto:info@primeoncology.org)

### Delegates will receive:



Round trip economy air or train transportation



Hotel accommodation for 9 October 2009

## Agenda

### Friday 9 October 2009

19.30–22.00 Reception and Dinner

### Saturday 10 October 2009

08.30–08.50 Welcome, introduction & demographic questions  
*Peter Mulders, MD, PhD*  
*Lee Lokey, MD, Senior Medical Director, PRIME Oncology*

08.50–09.20 **Case #1**—High-risk renal cell carcinoma: The emerging role of adjuvant and neoadjuvant therapy  
*Alastair W. S. Ritchie, MD*

09.20–09.50 **Case #2**—Intermediate-risk renal cell carcinoma: Best choice and sequencing of therapy  
*Camillo Porta, MD*

09.50–10.30 **Interactive debate**—Renal cell carcinoma: Is there a need for another VEGF tyrosine kinase inhibitor?  
Pro: *Thomas Powles, MD*  
Contra: *Peter Mulders, MD, PhD*

10.30–11.00 **Break**

11.00–11.20 Clinical Opinion Poll

11.20–11.55 **Case #3**—PSA-only relapse following local therapy for high-risk prostate cancer  
*Kurt Miller, MD*

11.55–12.25 **Case #4**—Transitional cell carcinoma of the bladder: What's the best approach?  
Discussant: *Thomas Powles, MD*  
Commentary: *Alastair W. S. Ritchie, MD*

12.25–13.00 **Case #5**—Nonseminomatous germ cell tumor of the testis: A multidisciplinary approach  
Discussant: *Kurt Miller, MD*  
Commentary: *Camillo Porta, MD*

13.00–14.00 **Lunch**

14.00–14.40 **Case #6**—Hormone-responsive prostate cancer with bone metastases: How should therapy be sequenced?  
*Peter Mulders, MD, PhD*

14.40–15.10 **Case #7**—Castration-resistant prostate cancer: Optimal management of a patient with good performance status  
*Camillo Porta, MD*

15.10–15.30 Ask the Experts

15.30 Concluding Remarks